TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04212221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD013 monotherapy
Description: MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD013 in combination with Brivanib Alaninate
Description: After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
Study: NCT02996175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Sleep Treatment
Description: 1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care sleep treatment enhanced with psychoeducation
Description: 1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns
Study: NCT00562081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 24/7 access to a Certified Asthma Educator

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Patient does not have 24/7 access to a Certified Asthma Educator.
Study: NCT01592773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride (HCl)
Description: During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily.
Study: NCT00087594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
Study: NCT01745666

Intervention type: OTHER
Group type: OTHER
Intervention: Epinephrine test
Description: Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epinephrine test
Description: Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
Study: NCT00087594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
Study: NCT01199744

Intervention type: DRUG
Intervention: zanamivir
Description: zanamivir
Study: NCT00579956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
Study: NCT00087594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
Study: NCT01000467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probucol
Description: group 3: 250 mg 1 tablet in the morning and evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probucol
Description: group 1: 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probucol
Description: group 2: 250 mg 2 tablets at once in the morning
Study: NCT01489683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 3 ml of 4% lidocaine was instilled to larynx and trachea
Study: NCT00579956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
Study: NCT01433510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazax
Description: 1 tablet/day - pre and co-seasonal
Study: NCT06381752

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous passive motion
Description: Daily application of continuous passive motion
Study: NCT00568750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
Study: NCT01489683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: 3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
Study: NCT02877524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation
Description: ASV during NIV
Study: NCT06381752

Intervention type: OTHER
Group type: OTHER
Intervention: standard rehabilitation
Description: standard rehabilitation program with group physiotherapy
Study: NCT04060589

Intervention type: OTHER
Intervention: Tissue donation
Description: Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
Study: NCT02877524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: PSV during NIV
Study: NCT00454922

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: no intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: meet with trained glaucoma educator 6 times over life of study
Study: NCT03489356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addressing Behavior Change (ABC)
Description: The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
Study: NCT03335059

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Synergo® RITE + MMC
Description: Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
Study: NCT02284711

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar electric energy
Description: Coagulation during salpingectomy using conventional bipolar electric energy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound energy
Description: Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
Study: NCT04060589

Intervention type: OTHER
Intervention: Blood Donation
Description: Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
Study: NCT00519935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy
Description: MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
Study: NCT01156675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXUS(TM) Interspinous Spacer
Description: Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XSTOP® Interspinous Spacer
Description: Treatment of lumbar spinal stenosis with the XSTOP® Spacer
Study: NCT04060589

Intervention type: OTHER
Intervention: Urine Donation
Description: Urine will be collected prior to prostate biopsy

Intervention type: OTHER
Intervention: Healthcare data linkage
Description: Men will consent to healthcare data linkage via national databases.
Study: NCT00390845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB681323
Description: 15 milligrams (mg)/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01026207

Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep study polysomnography compared with portable monitoring
Study: NCT00840775

Intervention type: DEVICE
Group type: OTHER
Intervention: Catheterization, stent deployment
Description: Standard catheterization procedure including Bare Metal Stent deployment.
Study: NCT02617511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02935608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT01613625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elastography
Study: NCT02030379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QPL-CT
Description: Use the QPL-CT to prioritize questions
Study: NCT03629366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Description: Supported Employment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual
Study: NCT00038038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
Study: NCT00043810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
Study: NCT03892603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises program
Description: Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
Study: NCT02030379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QPL-CT
Description: Use the QPL-CT to prioritize questions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QPL-CT
Description: Use the QPL-CT to prioritize questions
Study: NCT00038038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
Study: NCT03652519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
Study: NCT03892603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercises program
Description: Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and advice
Description: Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
Study: NCT03652519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
Study: NCT00278499

Intervention type: BEHAVIORAL
Intervention: Cross-sectional surveys
Description: Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.

Intervention type: BEHAVIORAL
Intervention: Questionnaire/counseling
Description: An initial questionnaire and counseling will occur once in addition to post-test counseling.
Study: NCT01738854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracuff pressure by cuff pressure manometer
Description: 36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracuff pressure by cuff pressure manometer
Description: 36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
Study: NCT02003950

Intervention type: OTHER
Group type: OTHER
Intervention: Snack Condition Specification
Description: Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).

Intervention type: OTHER
Group type: OTHER
Intervention: Snack Condition Specification
Description: Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).

Intervention type: OTHER
Group type: OTHER
Intervention: Snack Condition Specification
Description: Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).

Intervention type: OTHER
Group type: OTHER
Intervention: Snack Condition Specification
Description: Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
Study: NCT01738854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracuff pressure by cuff pressure manometer
Description: 36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
Study: NCT03754712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
Study: NCT03501758

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Transabdominal ultrasound of the bowel for categorisation of disease activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Transabdominal ultrasound of the bowel for categorisation of disease activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of prouroguanyline and uroguanyline in full blood
Description: Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of prouroguanyline and uroguanyline in full blood
Description: Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
Study: NCT01265849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LI
Description: LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LI
Description: LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.